← Back

Chengdu Bright Eye Hospital Co. Ltd.

Bright Eye Hospital Group Co., Ltd. operates ophthalmic medical institutions in China through itself and its subsidiaries. Its services include refractive surgery, medical optometry and glasses fitting, cataract surgery, glaucoma treatment, strabismus and amblyopia care, pediatric ophthalmology, fundus disease treatment, oculoplastic surgery, lacrimal duct surgery, corneal disease treatment, and low vision and visual rehabilitation. The company is also involved in medical, hospital, and investment management, ophthalmological research, the sale of medical instruments and eyeglasses, cultural propagation, engineering renovation, and technology development. Formerly known as Chengdu Bright Eye Hospital Group Co., Ltd., it changed its name to Bright Eye Hospital Group Co., Ltd. in June 2025; it was founded in 2005 and is headquartered in Chengdu, China.

Country
Price · split & dividend adjusted
News & notes moving 301239.CS
301239.CS

Bright Eye Hospital Releases 2026 Interim Report: Net Profit of 88.1088 Million Yuan

Bright Eye Hospital released its 2026 interim report on August 29, 2026. During the reporting period, the company achieved total operating revenue of 1.602 billion yuan, net profit attributable to the parent company of 88.1088 million yuan, and net cash inflow from operating activities of 333 million yuan. The company's latest asset-liability ratio was 54.57 percent, an increase of 1.12 percentage points compared with the same period last year. Gross margin was 39.09 percent, a decrease of 2.01 percentage points from the previous quarter. Return on equity was 4.14 percent. Diluted earnings per share were 0.59 yuan. Total asset turnover was 0.34 times, and inventory turnover was 4.55 times, down 13.79 percent year on year. The company had 10,500 shareholders, and the top ten shareholders held 88.5141 million shares, accounting for 59.16 percent of total share capital.
301239.CS
Jiemian·21dRead more →
301239.CS▲2

Purui Eye Care first-half net profit attributable to parent rises 500.7% to 88.11 million yuan

Purui Eye Care released its 2026 interim report, showing first-half net profit attributable to the parent of 88.11 million yuan, up 500.7% year on year. Operating revenue was 1.6 billion yuan, up 9.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 93.59 million yuan, up 350.4% year on year. Net operating cash flow was 333 million yuan, up 35.7% year on year. In the second quarter, the company swung to a net profit attributable to the parent of 17.46 million yuan, compared with a loss of 12.61 million yuan in the same period last year. As of the end of the second quarter, total assets were 4.771 billion yuan, up 4.7% from the end of the previous year. The company said that during the reporting period it deliberately slowed the pace of external expansion and shifted its focus to organic growth and improved operating efficiency.
301239.CS ▲
财中社·22dRead more →
301239.CS▼

Bright Eye's controlling shareholder pledges 5 million company shares

Bright Eye's controlling shareholder, Chengdu Bright Eye Century Investment, has pledged 5 million of its company shares. This pledge accounts for 9.31% of Bright Eye Investment's holdings and 3.34% of the company's total share capital. Following this pledge, Bright Eye Investment has cumulatively pledged approximately 35.304 million company shares, representing 65.71% of its holdings and 23.6% of the company's total share capital.
301239.CS ▼
北京商报·47dRead more →
301239.CS

Puru Ophthalmology Appoints Gao Wen as General Manager

The board of directors of Puru Ophthalmology convened the fifth meeting of the fourth board, approving the appointment of Gao Wen as the company's general manager. In the first quarter of 2026, Puru Ophthalmology achieved revenue of 820 million yuan and a net profit attributable to the parent company of 70.65 million yuan.
301239.CS
财中社·71dRead more →
© 2026 MarketDXAsset